STK11 and non-small cell lung carcinoma: Previous clinical trials have shown a clinical benefit of the addition of MET in NSCLC patients undergoing immunotherapy [29, 30], but the small sample sizes and lack of evaluation of LKB1 mutations may have limited their conclusions.